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Abstract 
Background: To assess the microbiological growth 
and antibiotic sensitivity  pattern in ventilator 
associated pneumonia (VAP).  
Methods: In this descriptive study nasobronchial 
lavages (NBL) were obtained by using a suction 
tube. These samples were  processed using standard 
microbiological techniques. The frequency of the 
causative organisms was obtained by culturing the 
NBL samples on suitable media. The patients were 
analyzed by age, gender, the causative bacteria and 
their antibiotics susceptibility pattern. 
Results:A total of 48 cases of VAP were isolated. 
Monomicrobial infections were diagnosed in 32 
patients and polymicrobial infections were 
diagnosed in 16 patients.  Common causative agents 
were Acinetobacter baumanii, Klebsiella 
pneumoniae, Pseudomonas aeruginosa and 
Staphylococcus aureus and the least common were 
Proteus mirabilis, Klebsiella oxytoca, Acinetobacter 
johnsonii, Staphlococcus coagulase negative, Serratia 
odorifera, Serratia marcesens, Burkholderia cepacia, 
Citrobacter ferundii and Enterobacter cloacae. 
Conclusion:The etiological agents of VAP vary 
from common organisms to very resistant pathogens. 
With the increasing incidence of multi drug resistant 
organisms; its early isolation, detection, diagnosis 
and specific antibiotics are required to avoid 
hazardous outcomes. 
Key Words: Ventilator Associated Pneumonia 
(VAP), Antibiotic Sensitivity pattern 
 
Introduction 
      Nosocomial pneumonia presents at the time of 
admission but develops 48 – 72 hours after the 
patient’s stay in the hospital.1 An example of this is 
Ventilator Associated Pneumonia (VAP) which occurs 
in patients who have been on mechanical ventilation 
due to tracheostomy or intubation for more than 48 
hours.  Studies report a rate of 1 to 4 cases per 1000 
ventilator days which can rise up to 10 cases per 1000 
ventilator days in surgical patients and neonates . 2–4  It 
has shown that the risk of VAP is highest when the 
patient has just been admitted to the hospital and 
declines over the course of stay. It is estimated to be 
3% per day during the first 5 days of ventilation, 2% 
per day during the next 5-10 days of ventilation and 
only 1% after this. 5,6  
     VAP is a common cause of morbidity and mortality 
in the hospital setting. A mortality rate of 4-9% has 
been reported. 2 Thus, antimicrobial therapy should be 
started at once even if it causes a delay in diagnostic 
studies. 7–9  Inadequate antibiotic treatment has led to 
an increase in the incidence of multi – drug resistant 
(MDR) strains of pathogens, further exacerbating the 
threat posed by the disease. VAP caused by these 
organisms is popularly known as Late – Onset VAP. 
On the other hand, community – acquired VAP can be 
caused by sensitive microorganisms and is called Early 
– Onset VAP.  3,5   
Patients and Methods 
 This descriptive study was conducted over a period of 
2 years, in Department of Microbiology, Armed Forces 
Institute of Pathology from March 2011  to April 2013. 
Patients admitted in the intensive care unit of 
Combined Military Hospital, Rawalpindi , who 
developed  pneumonia after spending more than 48 
hours on mechanical ventilator,were included. 
Nasobronchial lavages (NBL) were obtained by using 
a suction tube. Samples were processed using 
standard microbiological techniques. The frequency of 
the causative organisms was obtained by culturing the 
NBL samples on suitable media. Samples were first 
subjected to Gram’s staining and then quantitative 
cultures were performed.  The samples received were 
initially inoculated on blood agar, chocolate agar and 
McConkey agar. Samples were incubated at 37o C 
under aerobic conditions in candle jar for 24 hours.  
The antibiotic resistance patterns of isolated 
microorganisms were determined by Kirby-Bauer disk 
diffusion method. The Gram negative organisms were 
tested with augmentin, piperacilin tazobactam, 
imipenem, ceftazidime, amikacin and gentamicin. 
Gram positive organisms were tested with 
erythromycin, clindamycin, augmentin, vancomycin, 
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ciprofloxacin, and gentamicin. All plates were checked 
for growth overnight and then after 24 and 48 h of 
incubation.  The organisms were primarily identified 
by colony morphology, microscopy of Gram’s stain 
and routine biochemical tests. Confirmation of the 
species level was done by API 20 E & API 20 NE 
(Biomerieux) where required.   
Results 
     A total number of 48 patients who developed VAP 
were included . VAP was more common in males 
(60.42%) and was  more prevalent(45.83%) in age 
group  31-60 years (Table 1).  
Table 1: Age wise Distribution of VAP 
Age (Y) No (%) 
0-30 13 (27.08) 
31-60 22(45.83) 
61-90 13(27.08) 
90> 0(0) 
 
Table 2:  Monomicrobial and  
polymicrobial growth in VAP 
Agent No (%) 
Monomicrobial 32 (66.67) 
Polymicrobial 16 (33.33) 
 
Table 3: Relationship between  VAP cases and 
associated bacteria 
Causative Agents No.(%) 
Acinetobacter baumannii 26 (36.11) 
Pseudomonas aureginosa 10(13.89) 
Klebsiella pneumoniae 10(13.89) 
Staphylococcus aureus 7(9.72) 
Eschrichia coli 5(6.94) 
Acinetobacter johnsonii 3(4.17) 
Serratia marcesens 2(2.78) 
Staphlococcus Coagulase Negative 2(2.78) 
Klebsiella oxytoca 2(2.78) 
Burkholderia cepacia 1(1.39) 
Citrobacter ferundii 1(1.39) 
Enterobacter cloacae 1(1.39) 
Proteus mirabilis 1(1.39) 
Serratia odorifera 1(1.39) 
Among the 48 VAP cases, 32 (66.67%) were 
monomicrobial (one bacterial specie isolated) and 16 
(33.33%) were polymicrobial (two or more bacterial 
species isolated), yielding a total of 72 bacterial isolates 
(Table 2). Acinetobacter baumanii was the most 
common pathogen causing VAP with 36.11% cases. 
This was followed by Pseudomonas aeruginosa and 
Klebsiella pneumoniae, each with 13.89% cases (Table 
3). Co-amoxiclav was resistant against  most of the 
organisms (Table 4and 5)   
 
Table 4: VAP- Susceptibility Pattern   
Antibiotics S* R** I*** 
Amikacin 14% 86% 0% 
C-amoxiclav 4% 96% 0% 
Ampicillin 11% 89% 0% 
Ceftriaxone 10% 88% 2% 
Ciprofloxacin 20% 78% 2% 
Cotrimoxazole 31% 69% 0% 
Doxycycline 37% 63% 0% 
Gentamicin 33% 67% 0% 
Imepenem 37% 63% 0% 
Meropenem 38% 58% 4% 
Piperacillin+ Tazobactam 41% 59% 0% 
Polymixin B 74% 23% 3% 
Tigecycline 46% 46% 8% 
Vancomycin 100% 0% 0% 
*S=Sensitive; **R=Resistant; ***I=Intermediate  
 
Table 5: Antibiotics susceptibility pattern of 
major bacterial pathogens causing VAP 
Antibiotics Susceptibility Pattern of Major Bacterial Pathogens 
causing VAP 
 Acinetoba
cter 
baumannii 
Esche
richia 
coli 
Klebsi
ella 
pneum
oniae 
Pseu
domo
nas 
aerugi
nosa 
Staphy
lococc
us 
aureus 
Amikacin 91.67% 40.0% 80% 60% 86.71% 
Co-amoxiclav 100% 60% 100% 100% 100% 
Ampicillin 95% 100% 100% 44.4% 100% 
Ceftriaxone 100% 100% 70% 0% 100% 
Ciprofloxacin 95.83% 100% 50% 40% 100% 
Cotrimoxazole 88% 100% 40% 55.5% 33.33% 
Gentamicin 80% 60% 80% 40% 100% 
Imipenem 95.65% 0% 50% 40% 100% 
Meropenem 100% 20% 0% 100% 0% 
Piperacillin + 
Tazobactam 
90.48% 25% 0% 50% 100% 
Polymyxin B 0% 0% 77.76% 0% 0% 
Tigecycline 80% 0% 55.56% 0% 0% 
Vancomycin 0% 0% 0% 0% 0% 
 
Discussion 
    VAP is one of the most frequent infections acquired 
by patients on ventilators. Although efforts have been 
made to eliminate it by better sterilization of 
respiratory equipment, VAP continues to be a common 
problem in patients on mechanical ventilation with 
rates ranging from 8-28%.  11 Studies reported decline 
in VAP as age increases, especially in old age.12-14  
Patients receiving mechanical ventilation may develop 
VAP due to aspiration of oropharyngeal flora. In our 
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study, 66.67% of the cases were monomicrobial while 
the minority (33.33%) was polymicrobial. The 
incidence of polymicrobial VAP seems dangerously 
high compared to much lower values of 13.4% 
reported by Saroj et al. and 12.3% by Singhal et al. 
5,15The etiological agents may be gram negative or 
gram positive bacteria. In our study, Acinetobacter 
baumanii outstripped the other pathogens as the 
leading cause of VAP (36.1%).   Rashid et al. also 
reported Acinetobacter baumaniia the most common 
pathogen among children followed by Pseudomonas 
aeruginosa.16  Moving on, Gupta et al. also reported the 
same organisms as the most common cause of VAP. 7  
A study in Saudi Arabia also showed similar results 
with the highest number of cases being reported for 
Klebsiella pneumoniae, followed by Pseudomonas and 
then Acinetobacter. 1 
       Infection by Acinetobacter baumanii specifically 
occurs in patients on mechanical ventilation in the ICU 
who have been previously treated with broad 
spectrum antibiotics such as third generation 
cephalosporins and carbapenams.17,18 It is difficult to 
treat as Acinetobacter baumaniican survive in the 
environment for long periods of time and develops 
multiple drug resistance.17,19,20  Carbepenams are 
usually the treatment of choice for 
Acinetobacterbaumanii. However, if treatment fails due 
to the development of resistance, these can be 
substituted with polymyxins (colistin and polymyxin 
B), sulbactam and tigeycycline.17,21 Our results stand 
proof of the following statement with high resistances 
of 95.65% and 100% reported for Imipenem and 
Meropenem respectively. Thus, polymyxin B (0% 
resistance) and tigecycline (80% resistance) are better 
therapeutic options in our setup. 
       The first line of treatment for Pseudomonas 
aeruginosa and Klebsiella pneumoniae are 
cephalosporins combined with aminoglycosides. The 
cephalosporin in our study, ceftriaxone, showed 
showed  70% resistance to Klebsiella pneumonae and 
0% to Pseudomonas aeruginosa. On the other hand, the 
aminoglycosides amikacin and gentamicin, were 
comparatively resistant: Klebsiellapneumoniae showed 
80% resistance to amikacin and gentamicin both while 
Pseudomonas aeruginoa showed a resistance of 60% 
and 40% to amikacin and gentamicin respectively. 
Thus, combination therapy is likely to yield better 
results than the use of a single drug. Charles et al. 
reported a similar sensitivity profile for the 
aminoglycosides together with 100% susceptibility of 
the bacteria to Piperacillin-tazobactam.22  
      Ciprofloxacin, a fluoroquinolone, is used for 
Escherichia coli with a resistivity of 100% .Pena et al. 
also showed that there has been an upward trend in 
the number of cases of ciprofloxacin resistant cases of 
bacteremia with increasing fluoroquinolone use. 23 A 
study carried out in Turkey reported only 33% 
resistance to ciprofloxacin  while another showed a 
resistivity of 29%.24,25 Vancomycin is the most 
efficacious drug for the elimination of Staphylococcus 
aureus species with 100% sensitivity.5,7  Meropenam 
also showed 100% sensitivity. There is variation in 
such results with a study in Peshawar reporting a 
resistance of 40.9%.26 Aminopenicillin-Coamoxiclav 
(amoxicillin with clavulinic acid) and ampicillin were 
at another extreme with resistances of 100% to both. 
This is consistent with other studies in Nigeria 
reporting complete resistance to ampicillin. 27 
Complete resistance was reported to amoxicillin  but 
Naeem et al. reported that the greater efficacy of the 
co-amoxiclav preparation with a resistance of 
45.6%.26,28Cotrimoxazole is an antibiotic that is used 
for a variety of infections. It shows significant 
sensitivity for almost all the bacterial isolates. A study 
carried out in 6 major cities of Pakistan showed 81.1% 
resolution of pneumonia in children given 
cotrimoxazole. Thus, it can be considered for the 
treatment of polymicrobial VAP. 29  
 
Conclusion 
Proper knowledge of the pathogens and early isolation 
followed by prevention of prolonged antibiotic 
therapy has the potential to reduce mortality rates. 
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